ReviewMolecular therapy. Advances2026
Fourth-generation gene editors: Integration-based genome engineering.
Review in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Large serine recombinase-mediated gene insertion for high-throughput screens: advantages, design principles, and applications.Nucleic acids research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gene editing has rapidly progressed from early methods into highly precise tools with immense therapeutic promise. While initial CRISPR-Cas9 systems revolutionized the field, the fact that they rely on double-strand breaks can lead to genomic instability and off-target effects, which calls for innovation. This review covers the advancements in fourth-generation gene editing technologies. Specifically, it focuses on diverse integrase systems that enable precise DSB-free DNA insertion. First, we explore site-specific recombinases like tyrosine recombinases (Cre, FLP), large serine recombinases (PhiC31, Bxb1), and bridge recombinases (IS622) that offer efficient DNA rearrangements. Next, we introduce DNA transposases, which cover a versatile cut and paste systems (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.